Zorginstituut Nederland’s Lecanemab Healt...

By HEOR Staff Writer

February 18, 2026

Dutch Health Insurance Rejects Lecanemab Coverage Zorginstituut Nederland's advisory letter dated 13 February 2026 recommends against including lecanemab (Leqembi®) in the Dutch basi...
Advancing Cancer Screening in Slovenia: A Pathway to Equitable Care
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
Strategic Vision and Infarmed 2026 Priorities for Regulatory Reform
South Africa Health Reform: Navigating Innovations and Challenges for 2026
European Pharma Competitiveness: A Cornerstone for EU Economic Resilience
National HealthTech Access: Transforming NHS Adoption and Equity
Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package
Launch of TrumpRx Drug Pricing: Savings on Essential Medications
Healthcare Innovation Trends Shaping the Future: Insights from the J.P. Morga...
Ozempic Public Funding Approval in Portugal: Key Insights and Implications
Risicoverevening Policy Updates: Key Amendments for 2022-2025 Explained
Latin America Pharma Growth: Boehringer Ingelheim’s Strategic Investmen...